JP2024522210A - 複素環系ｊａｋ阻害剤 - Google Patents

複素環系ｊａｋ阻害剤 Download PDF

Info

Publication number
JP2024522210A
JP2024522210A JP2023576366A JP2023576366A JP2024522210A JP 2024522210 A JP2024522210 A JP 2024522210A JP 2023576366 A JP2023576366 A JP 2023576366A JP 2023576366 A JP2023576366 A JP 2023576366A JP 2024522210 A JP2024522210 A JP 2024522210A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
phenyl
hydrogens
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023576366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522210A5 (https=
JPWO2022127869A5 (https=
Inventor
向陽 陳
育成 ▲パン▼
Original Assignee
北京諾誠健華医薬科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京諾誠健華医薬科技有限公司 filed Critical 北京諾誠健華医薬科技有限公司
Publication of JP2024522210A publication Critical patent/JP2024522210A/ja
Publication of JP2024522210A5 publication Critical patent/JP2024522210A5/ja
Publication of JPWO2022127869A5 publication Critical patent/JPWO2022127869A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023576366A 2020-12-18 2021-12-16 複素環系ｊａｋ阻害剤 Pending JP2024522210A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011495497.0 2020-12-18
CN202011495497.0A CN114644633B (zh) 2020-12-18 2020-12-18 杂环类jak抑制剂
PCT/CN2021/138842 WO2022127869A1 (zh) 2020-12-18 2021-12-16 杂环类jak抑制剂

Publications (3)

Publication Number Publication Date
JP2024522210A true JP2024522210A (ja) 2024-06-11
JP2024522210A5 JP2024522210A5 (https=) 2026-03-09
JPWO2022127869A5 JPWO2022127869A5 (https=) 2026-03-09

Family

ID=81990162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023576366A Pending JP2024522210A (ja) 2020-12-18 2021-12-16 複素環系ｊａｋ阻害剤

Country Status (7)

Country Link
US (1) US20240246984A1 (https=)
EP (1) EP4310088A4 (https=)
JP (1) JP2024522210A (https=)
CN (1) CN114644633B (https=)
AU (1) AU2021398704A1 (https=)
CA (1) CA3222404A1 (https=)
WO (1) WO2022127869A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518072A (ja) * 2010-01-29 2013-05-20 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ タンパク質キナーゼモジュレーターとしての６，７−ジヒドロイミダゾ［１，５−ａ］ピラジン−８（５ｈ）−オン誘導体
JP2017531672A (ja) * 2014-10-22 2017-10-26 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヤヌスキナーゼ阻害剤としてのエチルＮ−Ｂｏｃピペリジニルピラゾロピリドン類
WO2020227563A1 (en) * 2019-05-08 2020-11-12 Vimalan Biosciences, Inc. Jak inhibitors
JP2020533376A (ja) * 2017-09-15 2020-11-19 アドゥロ バイオテック，インク． ピラゾロピリミジノン化合物およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090306067A1 (en) * 2006-04-10 2009-12-10 Harald Engelhardt 2, 4-diaminopyrimidide derivates and their use for the treatment of cancer
WO2019074962A1 (en) * 2017-10-10 2019-04-18 Syros Pharmaceuticals, Inc. PYRROLOTRIAZINE COMPOUNDS AND METHODS FOR INHIBITING TAM KINASES
JP2022510980A (ja) * 2018-11-30 2022-01-28 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ヘテロ芳香族誘導体調節因子、その製造方法及び使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518072A (ja) * 2010-01-29 2013-05-20 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ タンパク質キナーゼモジュレーターとしての６，７−ジヒドロイミダゾ［１，５−ａ］ピラジン−８（５ｈ）−オン誘導体
JP2017531672A (ja) * 2014-10-22 2017-10-26 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヤヌスキナーゼ阻害剤としてのエチルＮ−Ｂｏｃピペリジニルピラゾロピリドン類
JP2020533376A (ja) * 2017-09-15 2020-11-19 アドゥロ バイオテック，インク． ピラゾロピリミジノン化合物およびその使用
WO2020227563A1 (en) * 2019-05-08 2020-11-12 Vimalan Biosciences, Inc. Jak inhibitors

Also Published As

Publication number Publication date
US20240246984A1 (en) 2024-07-25
WO2022127869A1 (zh) 2022-06-23
AU2021398704A1 (en) 2024-03-21
EP4310088A1 (en) 2024-01-24
CA3222404A1 (en) 2022-06-23
CN114644633B (zh) 2026-02-03
CN114644633A (zh) 2022-06-21
EP4310088A4 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
HK1223100A1 (zh) 杂环化合物
ES2770693T3 (es) Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon
JP7821812B2 (ja) ヤヌスキナーゼ阻害剤としてのヘテロ環誘導体
CN109790158B (zh) 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途
JP7669063B2 (ja) Ｂｔｋ阻害剤としての架橋二環式化合物
BR112016012262B1 (pt) Acrilamidas heterocíclicas farmaceuticamente ativas e composições para tratar e prevenir condições mediadas por jac
EP3768272B1 (en) Jak inhibitors
BR112021014709A2 (pt) Compostos piridina ou piridazina dissubstituídos por amida
TWI851747B (zh) 介導酪氨酸激酶2活性的雜環化合物
JP2019532092A (ja) Ｉｌ−１２、ｉｌ−２３および／またはｉｆｎアルファ応答の調節剤として有用なヘテロ二環化合物
CN114478520A (zh) Bcl-2蛋白凋亡诱导剂及应用
CN114644633B (zh) 杂环类jak抑制剂
JP2022525006A (ja) Ｉｌ－１２、ｉｌ－２３、および／またはｉｆｎアルファ応答の調節剤として有用なイミダゾピリダジン化合物
CA3100095C (en) Indoline-1-carboxamide compound, preparation method therefor and medical use thereof
WO2025104122A1 (en) Heterocyclic derivatives as janus kinase inhibitors
EP4583976A1 (en) Heterocyclic derivatives as janus kinase inhibitors
HK40095618A (zh) 作为btk抑制剂的桥联双环化合物
CN121471240A (zh) 一种二吡唑并嘧啶类化合物及其合成方法与应用
CN116730978A (zh) 一类含杂芳环炔基化合物及其制备方法和用途
HK40042275B (en) Indoline-1-formamide compound, preparation method therefor, and medical use thereof
HK40004455B (en) Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof
HK40004455A (en) Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof
HK40042275A (en) Indoline-1-formamide compound, preparation method therefor, and medical use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251226

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20260227

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260407